<DOC>
	<DOCNO>NCT00653042</DOCNO>
	<brief_summary>The purpose study assess effect nesiritide compare placebo give standard care therapy , kidney function , heart function need treatment heart failure patient undergoing heart bypass graft surgery require use cardiopulmonary bypass machine ( CPB pump heart-lung machine ) .</brief_summary>
	<brief_title>Clinical Study Evaluate Nesiritide Patients Undergoing Coronary Artery Bypass Graft ( CABG ) Surgery A014 / NAPA</brief_title>
	<detailed_description>In coronary heart disease ( CHD ) , coronary artery become clogged calcium fatty deposit . The deposit , call plaque , narrow artery carry blood heart muscle could cause ischemic heart disease ( little blood oxygen reach heart muscle ) . Coronary Artery Bypass Graft ( CABG ) surgery treatment option ischemic heart disease . CABG surgery surgery create new route blood flow around narrow blocked artery heart muscle receive need oxygen nutrient . Acute kidney injury serious risk CABG surgery CPB pump ( heart-lung machine ) , could result ischemia follow surgery . This study double-blind ( neither patient doctor know whether patient assign receive study drug placebo ) , randomize ( assign treatment chance ) , placebo-controlled ( study drug result compare placebo result ) study determine effectiveness nesiritide compare placebo give HF patient undergo CABG surgery require use CPB pump . Patients enrol study 250 patient receive study drug placebo . Patients randomize one two treatment group 1:1 ratio ( nesiritide plus standard care : placebo plus standard care ) within site . Study medication administration initiate measurement qualify baseline hemodynamics prior chest incision . Nesiritide placebo administer continuous IV infusion rate 0.01 mcg/kg/min minimum 24 hour maximum 96 hour . Patients follow 30 day start study drug . All patient may receive additional standard care medication include inotropes , pressor , vasopressin , antiarrhythmic , diuretic , nitrate , nitric oxide need . Patient safety monitor throughout study physical exam , vital sign ( heart rate , blood pressure , respiratory rate , temperature ) , blood test , side effect . A follow-up communication 180 day start study drug implement collect mortality data . The patient assign nesiritide group receive continuous I.V . infusion 0.010 mcg/kg/min nesiritide least 24 hour could extend 96 hour . The patient assign placebo group receive match placebo .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Natriuretic Peptide , Brain</mesh_term>
	<criteria>NYHA class IIIV CHF Presenting CABG without mitral valve repair replacement procedure Planned utilization CPB Documentation leave ventricular ejection fraction ( LVEF ) less equal 40 % measure nuclear scan , echocardiogram ( ECHO ) , ventriculogram , within 90 day prior surgery . Planned aortic valve replacement repair Ongoing chronic dialysis ( either hemodialysis continuous ambulatory peritoneal dialysis ) Restrictive obstructive cardiomyopathy , constrictive pericarditis , pericardial tamponade , condition cardiac output dependent venous return Documented suspect low cardiac filling pressure Any known congenital heart disease Known allergic reaction sensitivity nesiritide excipients Females childbearing potential positive serum pregnancy test , nurse mother Treated investigational drug device within last 30 day document fever ( &gt; 101 degree F ) within 72 hour surgery WBC &gt; 15,000/mm3 within 72 hour surgery Documented bacterial/fungal/viral infection require administration IV antibiotic within 7 day surgery Pulmonary disease ( COPD , asthma condition ) require inpatient medical surgical treatment within 60 day surgery . Treatment exclusion criterion ( obtain anesthesia induction chest incision prior start study drug ) include : mean pulmonary artery pressure consistently &lt; equal 15mmHg central venous pressure consistently &lt; 6 mmHg systolic blood pressure consistently &lt; 90 mmHg . Use openlabel nesiritide within 48 hour study drug administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Myocardial Ischemia</keyword>
	<keyword>kidney failure</keyword>
	<keyword>CABG</keyword>
	<keyword>cardiopulmonary bypass ( CPB ) pump</keyword>
	<keyword>Coronary Artery Bypass Surgery</keyword>
	<keyword>heart surgery</keyword>
	<keyword>nesiritide</keyword>
	<keyword>Coronary Heart Disease</keyword>
</DOC>